IOM prioritizes OTC contraceptive, supplement research
This article was originally published in The Tan Sheet
Executive Summary
An Institute of Medicine 1report to Congress on priority topics for comparative effectiveness research lists research on "innovative strategies for preventing unintended pregnancies" - including OTC access to oral contraceptives and other hormonal methods - as a top-tier priority. Lower-level items in the inventory of 100 priorities include comparing the effectiveness of dietary supplements in treating prevalent conditions, smoking-cessation strategies in minority and adolescent populations, and consumer self-care in avoiding early morbidity among people with mental illness. IOM submitted the report June 30 as required by the American Recovery and Reinvestment Act of 2009. The law charged IOM with recommending projects the Department of Health and Human Services should fund with the $1.1 billion allocated for CER (2"The Tan Sheet" March 16, 2009)
You may also be interested in...
Baucus Maintains Public/Private Comparative Effectiveness Vision
Senate Finance Committee Chairman Max Baucus continues planning to include comparative effectiveness in the health care reform debate, even with research funding included in the American Recovery and Reinvestment Act
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.